Talk:Amylin

From Wikipedia, the free encyclopedia
Jump to: navigation, search
WikiProject Medicine (Rated B-class, Low-importance)
WikiProject icon This article is within the scope of WikiProject Medicine, which recommends that this article follow the Manual of Style for medicine-related articles and use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.
B-Class article B  This article has been rated as B-Class on the project's quality scale.
 Low  This article has been rated as Low-importance on the project's importance scale.
 
WikiProject Molecular and Cellular Biology (Rated B-class, Mid-importance)
WikiProject icon This article is within the scope of the WikiProject Molecular and Cellular Biology. To participate, visit the WikiProject for more information.
B-Class article B  This article has been rated as B-Class on the project's quality scale.
 Mid  This article has been rated as Mid-importance on the project's importance scale.
 

This article has comments here.

I think that this info is out of date; at least some of the functions of amylin are known. The "beta cell" page should also be updated.

function of amylin[edit]

The function of amylin, at least patially, is to slow down gastric emptying and impact the rate of digestion. Lets get a good medical reference and add it into the article. Mbbradford 06:08, 23 November 2006 (UTC)

Stub?[edit]

Is this article still a stub? As little is known about amylin, there is little more to add at this time. Perhaps the stub template should be removed. mbbradford 22:28, 15 December 2006 (UTC)

WikiProject class rating[edit]

This article was automatically assessed because at least one WikiProject had rated the article as start, and the rating on other projects was brought up to start class. BetacommandBot 16:23, 10 November 2007 (UTC)

Role of IAPP in type 2 diabetes largely missing[edit]

The article is missing information on IAPP's role in type 2 Diabetes.--Biophysik (talk) 07:02, 6 October 2008 (UTC)

Missing leading PDB image[edit]

The image is of insulin-degrading enzyme, not IAPP. IAPP is bound to insulin degrading enzyme but cannot be seen in the structure. Appropriate pdb files would be 1kuw,3DGJ, or 3DG1.--Biophysik (talk) 07:01, 6 October 2008 (UTC) Recommend to move article to Mid importance in MCB project in light of more recent information on its role in Type II diabetes--Biophysik (talk) 01:22, 29 October 2008 (UTC)

Merge[edit]

The article Proislet Amyloid Polypeptide contains a substantial amount of relevant content. I don't think separating the two really makes that much sense, because the biology of the processing is so relevant to each. I'm just going to go ahead and merge quickly; if there are objections it's always revertible. Wnt (talk) 10:13, 4 February 2012 (UTC)

Insulin co-secretion ratios.[edit]

"It is cosecreted with insulin from the pancreatic β-cells in the ratio of approximately 100:1."

That presumably is ration of insulin:amylin, however I could find no support for such a large number in the literature. Typical cited ratios range from 10:1 to 45:1. 172.5.154.148 (talk) 19:08, 28 September 2013 (UTC)

Amylin is the primary actor in both Type-II Diabetes Mellitus and Alzheimers.[edit]

Amylin and Insulin are co-produced by B-cells in response to high blood glucose, glucose in the duodenum, and other factors. They are generally produced in a fixed ratio, though serum glucagon will alter this ratio (how much and which direction was behind a paywall...). However (as with all things biological) that's a bit oversimplified.

The B-cells actually produce pro-Insulin & pro-Amylin, which are then converted to Insulin, pro-Insulin-C-Peptide, and Amylin before being released into the blood. Insulin & pro-Insulin-C-Peptide are produced in equal amounts by protease cleavage of the pro-Insulin. Amylin (and no doubt some sort of pro-Amylin-C-peptide no one has discovered yet) are produced in a much smaller amount by (it is claimed) the same protease. Not that that detail really matters.

One part that does matter is that administering Insulin without its C-peptide is unnatural and hence, unsurprisingly, unhealthy.

Insulin is removed from the system primarily by Insulin-Degrading Enzyme (IDE), which is also responsible for degrading amyloids, the primary causes of cell death in Type-II DM and Alzheimer's.

In the presence of sustained excess Insulin & Amylin production — generally caused by sustained overconsumption of carbohydrates — some of the pro-Amylin is not converted to Amylin, presumably because of a lack of sufficient protease. Whether this is caused directly by competition from proInsulin or is simply exhausted by too much proAmylin is unclear (i.e. whether the problem is too much proAmylin, or too much proAmylin + proInsulin); it's also possible that a separate nutritional issue is causing an undersupply of the protease, but this potential mechanism has gone unexplored. The proAmylin forms the nucleus of amyloid plaques — definitely in the beta cells and probably in brain and other places. Then the oversupply of Insulin needing IDE keeps the amyloids from being properly degraded. Cell death ensues, resulting in variously Alzheimer's and Type-II DM. 172.5.154.148 (talk) 19:31, 28 September 2013 (UTC)

This makes no sense[edit]

"Initially, the proIAPP aggregates inside the cell. The proIAPP acts as a seed, collecting IAPP from neighboring cells and forming an intracellular amyloid. As the amyloid grows, it spreads outside of the cell. The extracellular amyloid begins to excrete IAPP to other cells, inducing similar amyloid formation in other β-cells."

I'm going to do an initial repair, but someone should check me on it.

173.25.54.191 (talk) 19:37, 16 December 2013 (UTC)